Neurological disease: Are systems approaches the way forward?

Pharmacopsychiatry

Volumn 41, Issue SUPPL. 1, 2008, Pages

  Le Novere N ^a  

^a EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN;

ARTICLE; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; METABOLISM; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SOMATIC MUTATION; SYMPTOMATOLOGY;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; NERVOUS SYSTEM DISEASES; SYSTEMS BIOLOGY;

EID: 54749136929     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1080913     Document Type: Article

References (39)

1. Braver TS, Barch DM, Cohen JD. Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function. Biol Psychiatry 1999; 46: 312-328
2. Brown JW, Bullock D, Grossberg S. How laminar frontal cortex and basal ganglia circuits interact to control planned and reactive saccades. Neural Netw 2004; 17: 471-510
3. Butcher J. Neuroproteomics comes of age. Lancet 2007; 6: 850-851
4. Calabresi P, Picconi B, Parnetti L, DiFilippo M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 2006; 5 (11): 974-983
5. Calzone L, Gelay A, Zinovyev A, Radvanyi F, Barillot E. A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Sys Biol 2008, in the press
6. Camargo LM, Collura V, Rain JC, Mizuguchi K, Hermjakob H, Kerrien S, Bonnert TP, Whiting PJ, Brandon NJ. Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psych 2007; 12: 74-86
7. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994; 330: 681-690
8. Contreras-Vidal JL, Stelmach GE. A neural model of basal ganglia-thalamocortical relations in normal and parkinsonian movement. Biol Cybern 1995; 73: 467-476
9. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005; 74: 29-52
10. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26: 365-384
11. Cutsuridis V, Perantonis S. A neural network model of Parkinson's disease bradykinesia. Neural Netw 2006; 19: 354-374
12. Exner N, Treske B, Paquet D, Holmström K, Schiesling C, Gispert S, Carballo-Carbajal I, Berg D, Hoepken HH, Gasser T, Krüger R, Winklhofer KF, Vogel F, Reichert AS, Auburger G, Kahle PJ, Schmid B, Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007; 27: 12413-12418
13. Fernandez E, Schiappa R, Girault JA, Le Novère N. DARPP-32 is a robust integrator of dopamine and glutamate signals. PLoS Comput Biol 2006; 2: e176
14. Garcia L, D'Alessandro G, Fernagut PO, Bioulac B, Hammond C. Impact of high-frequency stimulation parameters on the pattern of discharge of subthalamic neurons. J Neurophysiol 2005; 94: 3662-3669
15. Gupta S, Bisht SS, Kukreti R, Jain S, Brahmachari SK. Boolean network analysis of a neurotransmitter signaling pathway. J Theor Biol 2007; 244: 463-469
16. Han SD, Nestor PG, Shenton ME, Niznikiewicz M, Hannah G, MacCarley RW. Associative memory in chronic schizophrenia: a computational model. Schizophr Res 2003; 61: 255-263
17. Humphries MD, Stewart RD, Gurney KN. A physiologically plausible model of action selection and oscillatory activity in the basal ganglia. J Neurosci 2006; 26: 12921-12942
18. Kaushik P, Gorin F, Vali S. Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis. J Comput Neurosci 2007; 22: 147-160
19. Justice JB, Nicolaysen LC, Michael AC. Modeling the dopaminergic nerve terminal. J Neurosci Methods 1988; 22: 239-252
20. Le Novère. The long journey to a Systems Biology of neuronal function. BMC Systems Biology 2007; 1: 28
21. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339: 1105-1111
22. Lindskog M, Kim M, Wikström MA, Blackwell KT, Kotaleski JH. Transient calcium and dopamine increase PKA activity and DARPP-32 phosphorylation. PLoS Comput Biol 2006; 2: e119
23. Mackie S, Millar JK, Porteous DJ. Role of DISC1 in neural development and schizophrenia. Curr Opin Neurobiol 2007; 17: 95-102
24. Markram H. The blue brain project. Nat Rev Neurosci 2006; 7: 153-160
25. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005; 28: 57-87
26. Nicholson C. Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum. Biophys J 1995; 68: 1699-1715
27. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova AM, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Medecine 2007; 13: 1102-1107
28. Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, Macdonald N, Wood NW, Martins ML, Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 2007; 9: 1243-1252
29. Rao SS, Hofmann LA, Shakil A. Parkinson's disease: diagnosis and treatment. Amer Family Phys 2006; 74: 2046-2054
30. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006; 52: 139-153
31. Ruppin E, Reggia JA, Horn D. Pathogenesis of schizophrenic delusions and hallucinations: a neural model. Schizophr Bull 1996; 22: 105-123
32. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116: 1744-1754
33. Schapira AHV, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Disc 2006; 5: 845-854
34. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neuro-degenerative diseases. Neurochem Int 2007; 51: 105-111
35. Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J 2004; 80: 452-458
36. Traub R, Wong RSK. Cellular mechanism of neuronal synchronisation in epilepsy. Science 1982; 216: 745-747
37. Traub R, Contreras D, Cunningham M, Murray H, LeBeau F, Roopun A, Bibbig A, Wilent W, Higley M, Whittington M. Single-column thalamocortical network model exhibiting gamma oscillations, sleep spindles, and epileptogenic bursts. J Neurophysiol 2005; 93: 2194-2232
38. Weihofen A, Ostaszewski B, Minami Y, Selkoe DJ. Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Hum Mol Genet 2008; 17: 602-616
39. Wolf JA, Moyer JT, Lazarewicz MT, Contreras D. Benoit-Marand M, O'Donnell P, Finkel LH. NMDA/AMPA ratio impacts state transitions and entrainment to oscillations in a computational model of the nucleus accumbens medium spiny projection neuron. J Neurosci 2005; 25: 9080-9095